Dr. Martens (LON:DOCS) Trading Down 2.6% – What’s Next?

Dr. Martens plc (LON:DOCS)’s stock price traded down 2.6% during mid-day trading on Friday . The company traded as low as GBX 74.40 and last traded at GBX 74.60. 13,891,834 shares changed hands during mid-day trading, an increase of 471% from the average session volume of 2,434,104 shares. The stock had previously closed at GBX 76.60.

Analyst Ratings Changes

Several equities research analysts have weighed in on DOCS shares. Peel Hunt restated a “buy” rating on shares of Dr. Martens in a report on Thursday, November 20th. Berenberg Bank restated a “buy” rating on shares of Dr. Martens in a research note on Thursday, November 27th. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of GBX 6,000.

Dr. Martens Price Performance

The stock has a fifty day moving average of GBX 80.37 and a 200-day moving average of GBX 83.28. The company has a quick ratio of 1.13, a current ratio of 2.85 and a debt-to-equity ratio of 127.27. The stock has a market capitalization of £720.89 million, a price-to-earnings ratio of 43.88, a P/E/G ratio of 6.40 and a beta of 0.11.

Dr. Martens (LON:DOCS) last released its quarterly earnings data on Thursday, November 20th. The company reported GBX (0.90) earnings per share for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. On average, equities research analysts predict that Dr. Martens plc will post 2.5809394 EPS for the current fiscal year.

Insider Buying and Selling at Dr. Martens

In related news, insider Robert Hanson purchased 96,000 shares of Dr. Martens stock in a transaction that occurred on Friday, December 5th. The stock was purchased at an average cost of GBX 79 per share, with a total value of £75,840. Also, insider Ije Nwokori sold 298,675 shares of the company’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of GBX 90, for a total transaction of £268,807.50. Insiders have purchased a total of 97,330 shares of company stock worth $7,696,090 over the last quarter. 2.79% of the stock is owned by company insiders.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.